-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Pfizer reported top-line results from the Phase II/III EPIC-PEP study, showing that Paxlovid failed to significantly reduce the risk of contractingCOVID-19
Infection with COVID-19
The latest analysis assessed data from 2,957 adults
The results showed that compared to placebo, people who took the 5-day course of Paxlovid were 32 percent less likely to get an infection, and those who took the 10-day course were 37 percent less likely to get an infection
statistics
The oral antiviral drug is currently approved for conditional or emergency use in more than 60 countries, including the United States, to treat high-risk COVID-19 patients
The oral antiviral drug is currently approved for conditional or emergency use in more than 60 countries, including the United States, to treat high-risk COVID-19 patients
child
Meanwhile, AstraZeneca's long-acting monoclonal antibody Evusheld was launched in the United States under an emergency use authorization granted in December for pre-exposure prophylaxis against COVID-19 in certain adults and children under 12
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5560663 https://firstwordpharma.
com/story/5560663
Leave a comment here